U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07295847) titled 'A Study of AZD0120 in Autoimmune Diseases' on Oct. 16.
Brief Summary: This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
Study Start Date: Dec. 16
Study Type: INTERVENTIONAL
Condition:
Systemic Sclerosis
Idiopathic Inflammatory Myopathies
Rheumatoid Arthritis
Intervention:
BIOLOGICAL: AZD0120
CD19/BCMA Autologous CAR T-cell therapy product
Recruitment Status: NOT_YE...